GNTA earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -4.35. Updated 2026-07-23.
Genenta Science S.p.A (GNTA) Research Hub
Genenta Science S.p.A (GNTA) trades on NASDAQ, IT in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.8408 USD (-3.63%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.35, market cap 0.03B. This hub links to the full technical, earnings and options research available for GNTA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IT |
| Last close | 0.8408 USD (-3.63%) |
| 52-week range | 0.82 USD – 2.04 USD |
| Trend regime | Range |
| 14-day RSI | 14.1 (Oversold) |
| Trailing P/E | -4.35 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for GNTA
Covered Call on GNTA: how it works, illustrative setup around the real 0.8408 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GNTA: how it works, illustrative setup around the real 0.8408 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GNTA: how it works, illustrative setup around the real 0.8408 USD price, max profit/loss, breakeven and when to use it. Educational.
GNTA technical analysis: range, last 0.8408 USD, RSI 14.1, 52w range 0.82 USD–2.04 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GNTA in?
Genenta Science S.p.A (GNTA) is classified under Healthcare (Biotechnology), listed on NASDAQ, IT.
Is GNTA in an uptrend or downtrend?
As of 2026-09-11, GNTA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GNTA's trailing P/E ratio?
GNTA's trailing P/E is -4.35, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does GNTA next report earnings?
GNTA is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.27409 USD.